-
Something wrong with this record ?
Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding
J. Mlcouskova, J. Stepankova, V. Brabec,
Language English Country Germany
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- DNA chemistry drug effects MeSH
- Photochemical Processes radiation effects MeSH
- Carboplatin chemistry pharmacology radiation effects toxicity MeSH
- Kinetics MeSH
- Humans MeSH
- Tumor Cells, Cultured MeSH
- Plasmids MeSH
- DNA Damage drug effects MeSH
- Cell Proliferation drug effects MeSH
- Antineoplastic Agents chemistry pharmacology radiation effects toxicity MeSH
- Drug Screening Assays, Antitumor MeSH
- Cattle MeSH
- Ultraviolet Rays MeSH
- Binding Sites drug effects MeSH
- Cell Survival drug effects MeSH
- Dose-Response Relationship, Drug MeSH
- Structure-Activity Relationship MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Cattle MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Carboplatin, an analogue of "classical" cis-diamminedichloridoplatinum(II) (cisplatin), is a widely used second-generation platinum anticancer drug. Cytotoxicity of cisplatin and carboplatin is mediated by platinum-DNA adducts. Markedly higher concentrations of carboplatin are required, and the rate of adduct formation is considerably slower. The reduced toxic effects in tumor cells and a more acceptable side-effect profile are attributable to the lower reactivity of carboplatin with nucleophiles, since the cyclobutanedicarboxylate ligand is a poorer leaving group than the chlorides in cisplatin. Recently, platinum complexes were shown to be particularly attractive as potential photochemotherapeutic anticancer agents. Selective photoactivation of platinum complexes by irradiation of cancer cells may avoid enhancement of toxic side-effects, but may increase toxicity selectively in cancer cells and extend the application of photoactivatable platinum complexes to resistant cells and to a wider range of cancer types. Therefore, it was of interest to examine whether carboplatin can be affected by irradiation with light to the extent that its DNA binding and cytotoxic properties are altered. We have found that carboplatin is converted to species capable of enhanced DNA binding by UVA irradiation and consequently its toxicity in cancer cells is markedly enhanced. Recent advances in laser and fiber-optic technologies make it possible to irradiate also internal organs with light of highly defined intensity and wavelength. Thus, carboplatin is a candidate for use in photoactivated cancer chemotherapy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13012666
- 003
- CZ-PrNML
- 005
- 20130411105658.0
- 007
- ta
- 008
- 130404s2012 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00775-012-0906-z $2 doi
- 035 __
- $a (PubMed)22638735
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Mlcouskova, Jarmila $u Department of Biophysics, Faculty of Science, Palacky University, Olomouc, Czech Republic.
- 245 10
- $a Antitumor carboplatin is more toxic in tumor cells when photoactivated: enhanced DNA binding / $c J. Mlcouskova, J. Stepankova, V. Brabec,
- 520 9_
- $a Carboplatin, an analogue of "classical" cis-diamminedichloridoplatinum(II) (cisplatin), is a widely used second-generation platinum anticancer drug. Cytotoxicity of cisplatin and carboplatin is mediated by platinum-DNA adducts. Markedly higher concentrations of carboplatin are required, and the rate of adduct formation is considerably slower. The reduced toxic effects in tumor cells and a more acceptable side-effect profile are attributable to the lower reactivity of carboplatin with nucleophiles, since the cyclobutanedicarboxylate ligand is a poorer leaving group than the chlorides in cisplatin. Recently, platinum complexes were shown to be particularly attractive as potential photochemotherapeutic anticancer agents. Selective photoactivation of platinum complexes by irradiation of cancer cells may avoid enhancement of toxic side-effects, but may increase toxicity selectively in cancer cells and extend the application of photoactivatable platinum complexes to resistant cells and to a wider range of cancer types. Therefore, it was of interest to examine whether carboplatin can be affected by irradiation with light to the extent that its DNA binding and cytotoxic properties are altered. We have found that carboplatin is converted to species capable of enhanced DNA binding by UVA irradiation and consequently its toxicity in cancer cells is markedly enhanced. Recent advances in laser and fiber-optic technologies make it possible to irradiate also internal organs with light of highly defined intensity and wavelength. Thus, carboplatin is a candidate for use in photoactivated cancer chemotherapy.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x chemie $x farmakologie $x účinky záření $x toxicita $7 D000970
- 650 _2
- $a vazebná místa $x účinky léků $7 D001665
- 650 _2
- $a karboplatina $x chemie $x farmakologie $x účinky záření $x toxicita $7 D016190
- 650 _2
- $a skot $7 D002417
- 650 _2
- $a proliferace buněk $x účinky léků $7 D049109
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a DNA $x chemie $x účinky léků $7 D004247
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a vztah mezi dávkou a účinkem léčiva $7 D004305
- 650 _2
- $a screeningové testy protinádorových léčiv $7 D004354
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kinetika $7 D007700
- 650 _2
- $a fotochemické procesy $x účinky záření $7 D055668
- 650 _2
- $a plazmidy $7 D010957
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a nádorové buňky kultivované $7 D014407
- 650 _2
- $a ultrafialové záření $7 D014466
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Stepankova, Jana $u -
- 700 1_
- $a Brabec, Viktor $u -
- 773 0_
- $w MED00005752 $t Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry $x 1432-1327 $g Roč. 17, č. 6 (2012), s. 891-8
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22638735 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130404 $b ABA008
- 991 __
- $a 20130411105929 $b ABA008
- 999 __
- $a ok $b bmc $g 975864 $s 810947
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2012 $b 17 $c 6 $d 891-8 $i 1432-1327 $m JBIC, Journal of biological inorganic chemistry $n J Biol Inorg Chem $x MED00005752
- LZP __
- $a Pubmed-20130404